TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01425463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous (II) Glycine Sulphate Complex
Description: Oral dose of 567.7 mg Ferrous (II) Glycine Sulphate Complex three times a day (t.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).~Administered orally with water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyferose
Description: Oral dose of 150 mg Polyferose Capsules twice daily (b.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).~Administered orally with water.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Ferrous (II) Glycine Sulphate Complex
Description: Administered orally with water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to Polyferose
Description: Administered orally with water.
Study: NCT00205920

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLVR Hydrogel
Description: 10 mL BLVR Hydrogel
Study: NCT04395053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1459
Description: TR group:~The first period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h.~RT group:~The first period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1459
Description: TR group:~The first period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h.~RT group:~The first period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h.
Study: NCT00629967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a and ribavirin
Description: pegylated interferon alpha 2a 180 mcg/week and ribavirin 1000-1200 mg/day for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a and ribavirin
Description: Pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
Study: NCT02852980

Intervention type: OTHER
Intervention: gestational diabetes women
Description: No intervention.
Study: NCT02312700

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Interactive empowerment tool
Study: NCT01788813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2245035
Description: Nasal spray solution, to be given intranasal, 80 ng/20 ng once weekly for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal Spray Solution, to be given intranasal, once weekly for 8 weeks
Study: NCT02312700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive empowerment tool
Study: NCT03762564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 on day 1, 8, 15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 on day 1, 8, 15
Study: NCT02907840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swisstom BB2
Description: Electrical impedance tomography lung monitoring uses a dedicated belt placed around patient's thorax to detect change in impedance due to change in aeration within the thorax
Study: NCT04175990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone Pill
Description: started from day 1 of menses till trigger day
Study: NCT02211911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium picosulfate
Study: NCT00945906

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FXIII Concentrate (Human) (FXIII)
Description: Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.~Subjects enrolled in this study who have not received at least 3 doses of FXIII Concentrate in a previous study of this product (i.e., NCT00640289, NCT00885742, or NCT00883090) will initially receive a dose of 40 U/kg by intravenous (IV) infusion.
Study: NCT04874051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: The experimental treatment will be provided by means of the OAK system. This device consists of 1 cabinet with 2 independent balance boards, 2 monitors (one for the physiotherapist and one for the patient) and 3 wireless IMUs (one for the left lower limb, one for the right lower limb and one for the trunk). The 2 balance boards provide body weight transfer exercises, while the wireless motion sensors provide one leg stance exercises or trunk exercises in a virtual environment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The Control Group will perform conventional balance exercises similar to the exercises provided with the OAK system.
Study: NCT02604329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oncolase Digi therapy laser diode
Description: The athermic phototherapy laser diode will be used by scanning the entire oral mucosa, including cheek and lip mucosa, gums, palate, tongue and floor of the mouth. It will be applied uniformly every two days as long as the grade of mucositis is 2 or more, with a fluence of 4J/cm², under two wavelengths (635 nm and 815 nm).~* Cheeks will be scanned extra-orally with laser fiber during 50 seconds, at the fluence of 4J/cm², associating two wavelengths : infra-red (815 nm, 3850mW) and red (635 nm, 150mW).~* Intra-orally, the fiber will be used to scan each area of mucositis during 30 seconds per area of 2 cm2, at 1cm from the mucosa; the power at 635 nm will be 150 milliwatts and 150 milliwatts at 815 nm.
Study: NCT03954340

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iRemember Neurofeedback (NFB)
Description: Neurofeedback (NFB) is a treatment technique based on learning with operant conditioning, in which a feedback (or a reward) is given in proportion with the desired physiological activity in order to improve cognition and/or behavior. This research will focus on EEG-NF where electrical activity measured with EEG serves as the physiological activity to be influenced.~EEG-NFB has been successfully used as a clinical tool for over 40 years treating various disorders from Autism , ADHD , Epilepsy , OCD and depression Electroencephalography (EEG) equipment is used to measure the electrical activity representing the neuronal activity of different parts of the brain.~During the treatment, electrode(s) are placed in predetermined location. Audio and visual rewards are given when the activity is measured to be within the desired frequency range.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: iRemember Neurofeedback (NFB)
Description: Neurofeedback (NFB) is a treatment technique based on learning with operant conditioning, in which a feedback (or a reward) is given in proportion with the desired physiological activity in order to improve cognition and/or behavior. This research will focus on EEG-NF where electrical activity measured with EEG serves as the physiological activity to be influenced.~EEG-NFB has been successfully used as a clinical tool for over 40 years treating various disorders from Autism , ADHD , Epilepsy , OCD and depression Electroencephalography (EEG) equipment is used to measure the electrical activity representing the neuronal activity of different parts of the brain.~During the treatment, electrode(s) are placed in predetermined location. Audio and visual rewards are given when the activity is measured to be within the desired frequency range.
Study: NCT01725659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Learning
Description: training of the hemiplegic upper limb with motor learning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Learning
Description: training of the hemiplegic upper limb with motor learning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Learning
Description: training of the hemiplegic upper limb with motor learning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotics
Description: subjects perform training of hemiplegic arm using an upper extremity robot

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surface FES
Description: subjects are provided with surface FES to the hemiplegic upper limb
Study: NCT03000296

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Hematopoietic stem cell transplantation Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
Study: NCT04487132

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active physical education lessons and physical education plan
Description: Active physical education lessons and physical education plan Including importance of physical activity and health, and physical education plan; through lecture in classroom will be provided to the contyrolled group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active physical education lessons and physical education plan
Description: Active physical education lessons and physical education plan Including importance of physical activity and health, and physical education plan; through lecture in classroom will be provided to the contyrolled group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recess or lunch time activities
Description: group intervention will be provided ti the experimental group which includes Preparing the playground by offering adequate spaces and games.Developing games and teaching children to play in recess time at-least 10-15 minutes daily(i.e.sport games, traditional games) Placing a sheet in the classroom with some reminders about being active in recess time (i.e. using a poster board encouraging playing one of the selected games )
Study: NCT02360462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after stimulation starts (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session
Study: NCT01479738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capitate bone grafting
Description: Capitate bone graft transfer for PIP joint reconstruction
Study: NCT03204266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine recovery supplement
Description: Participants take 1 ounce (30mls) of Arginine recovery supplement four times daily 5 days preoperatively and 14 days postoperatively.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids
Description: Participants given omega-3 fatty acids, 1 gram four times a day, 4 grams total per day. This will be started 7 days preoperatively and continued 14 days postoperatively.
Study: NCT02985593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4083

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01467687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: verapamil controlled release
Description: verapamil 300 mg controlled release capsule as a single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: verapamil controlled release
Description: verapamil 300 mg controlled release capsule as a single dose
Study: NCT03322709

Intervention type: PROCEDURE
Intervention: kidney transplant
Description: Transplantation of a kidney either by open surgery or robotic assisted laparoscopic surgery.

Intervention type: PROCEDURE
Intervention: kidney transplant
Description: Transplantation of a kidney either by open surgery or robotic assisted laparoscopic surgery.
Study: NCT00534443

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy of upper GI tract
Description: Upper GI endoscopy, one time on diagnosis and a second time 15 days after the end of the treatment. Gastric juice will be aspirated immediately after the entrance of the endoscope into the gastric lumen. Four biopsy specimens will be obtained from adjacent areas of the gastric antrum. Each biopsy will be used for in vitro culture. Blood will be sampled from one antecubital vein under aseptic conditions.~Each patient will be given antisecretory treatment and - if necessary- eradication treatment of H. pylori according to international guidelines.
Study: NCT02076022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced Fat Grafting
Description: The stromal vascular fraction (SVF) cell suspension (device output) will be processed using the Tissue Genesis Cell Isolation System™~The Standard graft material and the stromal vascular fraction cells will be mixed and subsequently injected into the amputated stump at a concentration of 2.0 - 3.0 x 10 6 stromal vascular cells/ml of injected fat graft to each site. The volume of each injected fat graft will depend on the volume requirements for each injured extremity.~To manually combine the standard fat graft material and the SVF suspension (device output), each of the syringes will be connected via luer to luer lock. The contents of the lipoaspirate syringe are transferred to the SVF syringe and the cell suspension will be injected slowly back and forth between the two (2) syringes. The final 1 mL SVF-fat graft syringe is now considered cell-enriched and ready for injection into the subject.
Study: NCT03355547

Intervention type: OTHER
Intervention: questionnaire about the severity of their symptoms of upper respiratory tract infection
Description: Before the operation, the researcher interviews the parents of the pediatric patients to check whether they have the upper respiratory tract infection and asks them to fill out a questionnaire about the severity of their symptoms. The questionnaire consists of 8 types of symptom about upper respiratory infections and each symptom was checked from 0 to 3 according to severity by their patients.

Intervention type: OTHER
Intervention: questionnaire about the severity of their symptoms of upper respiratory tract infection
Description: Before the operation, the researcher interviews the parents of the pediatric patients to check whether they have the upper respiratory tract infection and asks them to fill out a questionnaire about the severity of their symptoms. The questionnaire consists of 8 types of symptom about upper respiratory infections and each symptom was checked from 0 to 3 according to severity by their patients.
Study: NCT03400267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
Study: NCT04453943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton Walking - with or without FES
Description: The study involves validation of computer algorithms to estimate and control walking movements. The Rifton E-Pacer motorized walker, arm crutches, parallel bars, or a conventional walker may be used in order to assist donning and doffing of the exoskeleton system, standing, and walking for all subjects, at any time during experimentation. Walking movements will be elicited by the hybrid walking platform that combines a powered exoskeleton and an FES system. The powered exoskeleton can provide joint actuation at the hip and knee joints of a participant. The FES system can stimulate the quadriceps, hamstrings muscle, glutes, and ankle muscles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton Walking - with or without FES
Description: The study involves validation of computer algorithms to estimate and control walking movements. The Rifton E-Pacer motorized walker, arm crutches, parallel bars, or a conventional walker may be used in order to assist donning and doffing of the exoskeleton system, standing, and walking for all subjects, at any time during experimentation. Walking movements will be elicited by the hybrid walking platform that combines a powered exoskeleton and an FES system. The powered exoskeleton can provide joint actuation at the hip and knee joints of a participant. The FES system can stimulate the quadriceps, hamstrings muscle, glutes, and ankle muscles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton Sitting to Standing - with or without FES
Description: The study involves validation of computer algorithms to estimate and control sitting/standing movements. The Rifton E-Pacer motorized walker, arm crutches, parallel bars, or a conventional walker may be used in order to assist donning and doffing of the exoskeleton system, standing, and walking for all subjects, at any time during experimentation. Sitting/Standing movements will be elicited by the hybrid walking platform that combines a powered exoskeleton and an FES system. The powered exoskeleton can provide joint actuation at the hip and knee joints of a participant. The FES system can stimulate the quadriceps, hamstrings muscle, glutes, and ankle muscles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton Sitting to Standing - with or without FES
Description: The study involves validation of computer algorithms to estimate and control sitting/standing movements. The Rifton E-Pacer motorized walker, arm crutches, parallel bars, or a conventional walker may be used in order to assist donning and doffing of the exoskeleton system, standing, and walking for all subjects, at any time during experimentation. Sitting/Standing movements will be elicited by the hybrid walking platform that combines a powered exoskeleton and an FES system. The powered exoskeleton can provide joint actuation at the hip and knee joints of a participant. The FES system can stimulate the quadriceps, hamstrings muscle, glutes, and ankle muscles.
Study: NCT00950885

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Dose Melatonin
Description: Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose Melatonin
Description: Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
Study: NCT02773784

Intervention type: OTHER
Intervention: immunohistochemistry and/or FISH
Description: Patients with invasive breast cancer diagnosed by core needle biopsy (CNB) and not to receive neoadjuvant system therapy are eligible for this study. ER, PR, Her-2 and Ki67 are determined by immunohistochemistry (IHC) in CNB and surgical specimen. FISH analysis will be carried out in all HER2 2+ samples.
Study: NCT01120782

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A toric contact lens with new wetting agent
Description: Investigational toric contact lens made of etafilcon A material with a new wetting agent.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A toric contact lens with new wetting agent
Description: Investigational toric contact lens made of etafilcon A material with a new wetting agent.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A toric contact lens
Description: Marketed toric contact lens made of etafilcon A material.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A toric contact lens
Description: Marketed toric contact lens made of etafilcon A material.
Study: NCT03255629

Intervention type: DRUG
Group type: OTHER
Intervention: glucagon
Description: novel, stable non-aqueous glucagon formulation provided by Xeris Pharmaceuticals

Intervention type: DEVICE
Group type: OTHER
Intervention: Closed loop glucagon pump
Description: a novel closed-loop glucagon system (CLG) incorporating a novel, stable non-aqueous glucagon formulation together with an infusion pump system (Omnipod) guided by real-time continuous glucose monitoring (Dexcom) that is triggered by a hypoglycemia alert algorithm.

Intervention type: DEVICE
Group type: OTHER
Intervention: Closed loop glucagon pump
Description: a novel closed-loop glucagon system (CLG) incorporating a novel, stable non-aqueous glucagon formulation together with an infusion pump system (Omnipod) guided by real-time continuous glucose monitoring (Dexcom) that is triggered by a hypoglycemia alert algorithm.
Study: NCT02191215

Intervention type: DRUG
Intervention: Nevirapine (Viramune®)
Study: NCT04203277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVY
Description: a combination of practice education and quality improvement interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVY
Description: a combination of practice education and quality improvement interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVY
Description: a combination of practice education and quality improvement interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVY
Description: a combination of practice education and quality improvement interventions
Study: NCT02965092

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Second generation CAR-T cells